Response to the letter to the editor submitted by Jaiswal A et al. (2020) regarding 'efficacy and safety of saroglitazar in managing hypertriglyceridemia in type-2 diabetes: A meta-analysis' (Dutta et al.). Issue 6 (November 2020)